US and UK Healthcare Industry Professional are Positive UK Will Remain Attractive Destination for Healthcare Research Post-Brexit, says GlobalData

While post-Brexit regulatory changes continue to cause significant uncertainty for the UK’s healthcare sector, the UK Government’s initiatives, such as the Medicines and Medical Devices Act, provide much-needed opportunities to shape the environment for innovative healthcare following Brexit, says GlobalData a leading data and analytics company.
GlobalData’s latest report, ‘Brexit and the Healthcare Industry – 2021’, reveals that a total of 64% of US and 56% of UK healthcare industry professionals were positive towards the UK remaining an attractive destination for healthcare research and manufacturing post-Brexit. In contrast, the respondents from Europe (excluding the UK) were more negative, with only 24% of the respondents believing that the UK could be an attractive market.
Urte Jakimaviciute, Senior Director of Market Research at GlobalData, comments: “Compared to 2018 and 2019 survey results, the percentage of the US and UK respondents who believed that the UK would continue to be an attractive destination for healthcare research and manufacturing post-Brexit, increased by more than 10% in 2021. This shift may have been influenced by the finalization of the UK-EU Trade and Cooperation Agreement (TCA), the UK Government’s attempts to create legislative framework to promote the pharmaceutical sector and the MHRA’s intentions to join the US FDA’s coordinated Project Orbis, which is a global program to speed up patient access to innovative cancer treatments. Even though the vast majority of the respondents from Europe remained negative, their positivity also increased by 10% since 2019. This suggests that the UK-EU TCA provided some confidence in the UK healthcare sector post-Brexit.”
In the same survey, the majority of respondents across all regions highlighted that reducing barriers to UK-EU collaboration on clinical research, followed by close alignment to the EU’s drug approval system, would be the top two initiatives that could help the UK’s pharmaceutical industry to succeed post-Brexit.
Jakimaviciute continues: “The COVID-19 pandemic highlighted the importance of clinical research and its vital role in improving healthcare. It also showed that scientific innovation requires cross-nation collaboration, unrestricted access to information, and human resources. Any prospects of the UK-EU divergence on clinical trials regulation may compromise UK inclusions in multinational clinical trials. It is particularly important for research related to rare diseases and pediatric clinical trials, where patient populations are limited or strictly defined.”
The Medicines and Medical Devices Act 2021 is aimed at boosting the UK’s healthcare industry by supporting the availability and facilitating the access to medicines. The Act also supports new regulation for novel therapies, clinical trials, and makes provisions for the use of innovations in healthcare, such as artificial intelligence.
Jakimaviciute adds: “Even though separation from the EU may allow the UK to create a more efficient regulatory strategy, the UK will need to find a sustainable balance if the country wants to keep close alignment with the EU, while moving toward its own independent, commercially viable, and competitive regulatory regime. The Medicines and Medical Devices Act presents both challenges and opportunities for the UK healthcare sector. The UK’s ability to capitalize on opportunities and minimize risks will be crucial to determine the future of the country’s life sciences industry.”
Global Health & Pharma Magazine looks to keep readers and web users updated with the latest innovations and advancements within the pharmaceutical and healthcare industries.
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-advertisement | 1 year | Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category . |
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
CookieLawInfoConsent | 1 year | Records the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie. |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
zfccn | session | Zoho sets this cookie for website security when a request is sent to campaigns. |
Cookie | Duration | Description |
---|---|---|
_zcsr_tmp | session | Zoho sets this cookie for the login function on the website. |
Cookie | Duration | Description |
---|---|---|
__gads | 1 year 24 days | The __gads cookie, set by Google, is stored under DoubleClick domain and tracks the number of times users see an advert, measures the success of the campaign and calculates its revenue. This cookie can only be read from the domain they are set on and will not track any data while browsing through other sites. |
_ga | 2 years | The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors. |
_ga_7GTFNZD3Y9 | 2 years | This cookie is installed by Google Analytics. |
_gat_gtag_UA_63302014_1 | 1 minute | Set by Google to distinguish users. |
_gid | 1 day | Installed by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously. |
aigm_tracking_consent | 1 year | Created by Monster Tracking v2 for internal tracking/fingerprinting - determines whether the user has consented to being tracked by allowing cookies. |
aigm_tracking_id | 1 year | Created by Monster Tracking v2 for internal tracking/fingerprinting - contains the consent ID number of the user. |
iutk | 5 months 27 days | This cookie is used by Issuu analytic system to gather information regarding visitor activity on Issuu products. |
Cookie | Duration | Description |
---|---|---|
IDE | 1 year 24 days | Google DoubleClick IDE cookies are used to store information about how the user uses the website to present them with relevant ads and according to the user profile. |
mc | 1 year 1 month | Quantserve sets the mc cookie to anonymously track user behaviour on the website. |
test_cookie | 15 minutes | The test_cookie is set by doubleclick.net and is used to determine if the user's browser supports cookies. |
Cookie | Duration | Description |
---|---|---|
4662279173 | session | No description available. |
cookietest | session | No description |
GoogleAdServingTest | session | No description |
zabUserId | 1 year | No description available. |
zabVisitId | session | No description available. |
zft-sdc | 9 hours | No description |
zps-tgr-dts | 1 year | No description |
zsc5bf6c5dde2ed4839ad2d941ab4c83bfa | 30 minutes | No description |